Our News
Rise Therapeutics Completes Enrollment in Four-Week Dose Expansion Cohort for the R-2487 Rheumatoid Arthritis Clinical Trial
Rockville, Maryland – June 2, 2026 – Rise Therapeutics, a clinical-stage biotechnology company advancing novel oral immunotherapies for autoimmune diseases, today announced the completion of full enrollment in the 4-week dose expansion cohort of its Phase 1b clinical trial (NCT05961592) evaluating orally dosed R-2487 in patients with active rheumatoid arthritis (RA). Confirmation of the drug free, durability of clinical response marks a key inflection point in the program’s clinical development.
Rise Therapeutics Secures New Funding to Advance First-in-Class R-2487 Oral Immune Biomodulator into Sjogren’s Disease Clinical Testing
Rockville, Maryland — September 23, 2025— Rise Therapeutics, a clinical-stage biotechnology company developing a novel class of oral targeted immunotherapies, today announced it will be initiating clinical evaluation of R-2487 in SjD.
Rise Therapeutics Reports Ulcerative Colitis Dose Escalation Clinical Results for R-3750 at the Digestive Disease Week (DDW) Conference in San Diego May 3-6
Rockville, Maryland— April 7, 2025 — Rise Therapeutics, a biopharmaceutical company developing precision immunotherapies, today announced that it will report its first clinical results from the completed dose escalation segment of its R-3750 Phase 1 clinical trial in ulcerative colitis at the upcoming DDW conference in San Diego on May 6th.